Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Bemnifosbuvir/Ruzasvir in Severe Renal or Hepatic Impairment
NCT06911320Phase 1Completed
- Sponsor
- Atea Pharmaceuticals
- Start
- Apr 2025
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of bemnifosbuvir and ruzasvir in hepatitis C (HCV) (3 arms), sponsored by Atea Pharmaceuticals. Primary endpoints: Maximum plasma concentration at Day 1 and Area under the plasma concentration-time curve at Day 1. Started Apr 2025; status: completed.
02
Drugs
bemnifosbuvirruzasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT06911320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06911320.